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MicroRNAs (miRNAs) are 21 to 24 nucleotide small
non-coding RNA gene products that play important roles
in the regulation of eukaryotic gene expression by base
pairing with target mRNAs at the 3’-untranslated region;
they can leading to mRNA cleavage or translational
repression [1-3]. It has been suggested that miRNAs are
involved in various biological processes, including cell
proliferation, cell death, stress resistance, and fat
metabolism [4]. Moreover, several recent reports have
shown that miRNAs participate in human tumorigenesis
as tumor suppressors or oncogenes [5-7]. For example,
miRNA let-7, which targets the oncogene Ras, is
downregulated in lung cancer [8], whereas the miR-17-
92 cluster at 13q31.3 is reportedly overexpressed in lung
cancer [9]. Single nucleotide polymorphisms (SNPs) or
mutations in an miRNA sequence may alter miRNA
expression or maturation. Expression of miRNA could
have important consequences on the expression of the
various protein coding oncogenes and tumor suppressors
involved in malignant transformation. Furthermore, the
mechanism through miRNA expression can be caused
by genomic amplification [10], genomic deletion [11],
epigenetic alteration [12], and retroviral insertion
mutagenesis [13,14].
Recently, several miRNAs were used to screen for
common SNPs and the screening identified four SNPs
(rs2910164, rs2292832, rs11614913, and rs3746444) at
the pre-miRNA regions of miR-146a, miR-149, miR-
196a2, and miR-499, respectively. The rs11614913 SNP
in miR-196a2 was associated with a shortened survival
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Objectives: The microRNA (miRNA) miR-196a2 may play an important role in lung cancer development and survival by
altering binding activity of target mRNA. In this study, we evaluated their associations with the susceptibility of non-small
cell lung cancers (NSCLC) by case-control study in a Korean population.
Methods: We performed genotyping analyses for miR-196a2 rs11614913 T/C at miRNA regions in a case-control study
using blood samples of 406 NSCLC patient and 428 cancer-free control groups. 
Results: The total C allele frequencies for miR-196a2 were 48.8% for the patients and 45.6% for the controls; and the
genotype frequencies of TT, TC, and CC were 23.7%, 55.2%, and 21.1% for the patients and 31.1%, 46.35%, and 22.4%
for the controls (p<0.05). Participants who possesses TC/CC genotypes showed high risk for NSCLC compared to those
possessed TT genotypes (OR, 1.42; 95% CI, 1.03 to 1.96). The association was persisted in 60 and older age group, male,
smokers, those without family history for cancer. However, no significant association of CC genotypes in recessive genetic
model was observed. 
Conclusions: In conclusion, this case-control study provides evidence that miR-196a2 rs11614913 C/T polymorphisms
are associated with a significantly increased risk of NSCLC in a dominant model, indicating that common genetic
polymorphisms in miR-196a2 rs11614913 are associated with NSCLC. The association of miR196a2 rs11614913
polymorphisms and NSCLC risk require confirmation through additional larger studies. 
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cc time of non-small cell lung cancer (NSCLC) by altering
the expression of mature miR-196a and the binding
activity of target mRNA [15]. In addition, the miR-
196a2 may play an important role in lung cancer
development and survival by influencing the expression
and maturation of miRNAs [16]. 
In this study, we hypothesize that this functional SNP,
rs11614913 T/C in miR-196a2, is also associated with
lung cancer susceptibility in a Korean population. We
performed genotyping analyses of miR-196a2
rs11614913 T/C at miRNA regions and evaluated their
associations with the susceptibility of NSCLC in a case-
control study of 406 NSCLC patients and 428 cancer-
free controls in a Korean population.
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I. Study Subjects
The subjects of this study were members of a hospital-
based study population: they included 406 patients with
lung cancer and 428 cancer-free control subjects. Our
study was approved by the Institutional Review Board of
Chungbuk University and Dong-A University, and
written informed consent was obtained from all parti-
cipants or their representatives. All patients were
histopathologically diagnosed as having NSCLC and
were prospectively recruited into an ongoing study of
lung cancer molecular epidemiology that started in 2003.
Healthy volunteers for controls were recruited from
among the residents of Busan city by receive health
checkups for diseases of adult. They had no reported
current or past history of disorders. The age and sex
distributions were not significantly different among the
subjects in the NSCLC group and the control group. The
mean age was 67.310.2 for patients and 63.210.2
for control subjects. All subjects were interviewed in
accordance with a structured questionnaire to obtain
information on demographic data, including age, gender,
and residence. After the interview, a onetime sample of
approximately 3 to 5 mL of venous blood was collected
from each participant. 
II. DNA Extraction and Genotyping
Blood samples were collected in tubes that contained
EDTA. Genomic DNA was extracted from white blood
cell fractions by means of a Qiagen blood kit (Qiagen,
Chatsworth, CA, USA). Genotyping was performed with
a polymerase chain reaction (PCR). For genotyping of the
polymorphic sites, the amplifying primers and probes were
designed for TaqMan (Assay-on-demand ID;
C_31185852_10). A primer (Applied Biosystems, Foster
City, CA, USA) was used to design the PCR primers and
the MGB TaqMan probes. The miR-196a2 specific primers
were forward, 5’-CCAGGCTGGTCTCGAACTC-3’,
and reverse, 5’-CTGAATAAATGAGTTCTGCAAAA-
CAGGTT-3’. One allelic probe was labeled at the 5’ end
with the FAM dye (5’-CAAGTGATGCACCCAC-3’)
and at the other end with fluorescent VIC dye (5’-
CCTCAAGTGATTCACCCAC-3’). The PCRs were
run on a TaqMan Universal Master mix without UNG
(Applied Biosystems, Foster City, CA, USA) but with a
PCR primer concentration of 900 nM and a TaqMan
MGB-probe concentration of 200 nM. The reactions
were carried out in a 384-well format in a total reaction
volume of 5 uL with 20 ng of the genomic DNA. The
plates then were placed in a thermal cycler (PE 9700,
Applied Biosystems, Foster City, CA, USA) and heated to
50 C for 2 minutes and 95 C for 10 minutes; this step
was followed by 40 cycles of 95 C for 15 seconds and
60 C for 1 minute. Ten percent of the samples were
randomly selected for repeated genotyping for
rs11614913 T/C polymorphism, and the results were
100% concordant. The TaqMan assay plates were then
transferred to a Prism 7900HT instrument (Applied
Biosystems, Foster City, CA, USA), which we used to
measure the fluorescence intensity in each well of the
plate. The fluorescence data files from each plate were
analyzed with automated software (SDS 2.1).
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Table 1. Distribution of selected variables between
non-small cell lung cancer patient and control
subjects
Variables
n (%)
p-
value Patients 
n=406
Controls 
n=428
Age (y) (meanSD)
Age (y)
60
<6 0
Gender
Male
Female
Smoking status
Smokers
Non-smokers
Family history of cancer 
No
Yes
67.3  10.2
317 (78.1)
89 (21.9)
323 (79.6)
83 (20.4)
346 (85.2)
60 (14.8)
323 (79.6)
83 (20.4)
63.2  10.2
278 (64.9)
150 (35.1)
336 (78.5)
92 (21.5)
284 (66.4)
144 (33.6)
313 (73.1)
115 (26.9)
0.38
0.07
0.71
<0.01
0.08
SD: standard deviation.
p-value was revealed by two-sides Chi-square test."TTPDJBUJPO#FUXFFO.JDSP3/"B8JUI3JTLTPG/4$-$
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III. Statistical Analysis
A Chi-square test was used to evaluate differences
between the cases and controls in the frequency of the
selected demographic variables, including smoking
status, family history of cancer, and the genotype
distributions of the miR-196a T/C polymorphism. All
data were computed by binary logistic regression in the
program SPSS version 11.0 (SPSS Inc., Chicago, IL,
USA). The associations between the miR-196a T/C
polymorphism and the lung cancer risk were estimated
by computing the odds ratios (OR,) and their 95%
confident intervals (CIs) from both univariate and
multivariate logistic regression analyses.
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The baseline characteristics of the 406 NSCLC
patients and 428 control subjects included in the analysis
are summarized in Table 1. The distribution of age, sex,
and family history of cancer among NSCLC patients and
controls were comparable. As expected, the smoking
status has a statistically significant difference in the risk
factor for lung cancer in our study. About 85.2% of the
patients were smokers, which is significantly higher than
that of the controls (p < 0.01).
Table 2 shows the allele frequencies and genotype
distributions of miR-196a2 rs11614913 in the patients
and controls. The observed frequencies for this
Table 2. miR-196a allelic and genotype frequencies between non-small cell lung cancer patient and control
subjects and their association with non-small cell lung cancer risks
Variables
n (%)
Genotypes Patients (n=406) Controls (n=428) OR (95% CI)
p-value
Total
1
Age (y)
60
<60
Sex
Male
Female
T allele
C allele
TT
TC
CC
TC/CC
CC vs TC+TT
T allele
C allele
TT
TC
CC
TC/CC
CC vs TC+TT
T allele
C allele
TT
TC
CC
TC/CC
CC vs TC+TT
T allele
C allele
TT
TC
CC
TC/CC
CC vs TC+TT
T allele
C allele
TT
TC
CC
TC/CC
CC vs TC+TT
416 (51.2)
396 (48.8)
96 (23.7)
224 (55.2)
86 (21.1)
310 (76.4)
86 (21.2)
336 (51.7)
314 (48.3)
81 (24.9)
174 (53.5)
70 (21.5)
224 (75.1)
70 (21.5)
80 (49.4)
82 (50.6)
15 (18.5)
50 (61.7)
16 (19.8)
66 (81.5)
16 (19.8)
330 (51.1)
316 (48.9)
77 (23.9)
176 (54.5)
70 (21.7)
246 (76.2)
70 (21.7)
86 (51.8)
80 (48.2)
19 (22.9)
48 (57.8)
16 (19.3)
64 (77.1)
16 (19.3)
466 (54.4)
390 (45.6)
134 (31.3)
198 (46.3)
096 (22.4)
294 (68.7)
096 (22.4)
311 (53.8)
267 (46.2)
093 (32.2)
125 (43.3)
071 (24.6)
196 (67.8)
071 (24.6)
155 (55.8)
123 (44.2)
041 (29.5)
073 (52.5)
025 (18.0)
098 (70.5)
025 (18.0)
368 (54.8)
304 (45.2)
109 (32.4)
150 (44.6)
077 (22.9)
227 (67.6)
077 (22.9)
098 (53.3)
086 (46.7)
025 (27.2)
048 (52.2)
019 (20.7)
067 (72.8)
019 (20.7)
1.00
1.10 (0.90 - 1.35)
1.00
1.54 (1.10 - 2.17)
1.17 (0.77 - 1.76)
1.42 (1.03 - 1.96)
0.08 (0.62 - 1.25)
1.00
1.09 (0.87 - 1.36)
1.00
1.60 (1.10 - 2.33)
1.13 (0.73 - 1.77)
1.43 (1.01 - 2.03)
0.84 (0.58 - 1.23)
1.00
1.29 (0.88 - 1.90)
1.00
1.87 (0.94 - 3.74)
1.75 (0.74 - 4.14)
1.84 (0.94 - 3.59)
1.12 (0.56 - 2.25)
1.00
1.16 (0.93 - 1.44)
1.00
1.66 (1.15 - 2.39)
1.29 (0.83 - 1.99)
1.53 (1.09 - 2.16)
0.93 (0.64 - 1.34)
1.00
1.06 (0.70 - 1.61)
1.00
1.32 (0.64 - 2.70)
1.11 (0.45 - 2.71)
1.26 (0.63 - 2.50)
0.92 (0.44 - 1.93)
<0.36
<0.05
<0.05
<0.48
<0.46
<0.05
<0.05
<0.37
<0.2
<0.2
<0.07
<0.75
<0.18
<0.02
<0.01
<0.70
<0.79
<0.73
<0.51
<0.82
OR: odds ratio, CI: confidence interval.
p-value was revealed by two-sides Chi-square test.
1Adjusted for age, sex, and smoking status.polymorphism were in agreement with the frequencies
expected under the Hardy-Weinberg equilibrium in the
patients and controls (p = 0.66). As shown in Table 2,
the total allele frequencies for miR-196a C were 48.8%
for the patients and 45.6% for the controls. The total
genotype frequencies for TT, TC, and CC were 23.7%,
55.2%, and 21.1% for the patients and 31.1%, 46.3%,
and 22.4% for the controls (p < 0.05). Significant
associations were observed for the miR-196a2
rs11614913 CT/TT genotypes in a dominant model. The
logistic regression analyses reveal that after adjusting for
age, sex, and smoking status in a comparison with wild-
type carriers there appears to be an association between a
significantly increased NSCLC risk and variant
genotypes of the miR-196a2 rs11614913 CT/TT
genotypes (p < 0.05, OR, 1.42; 95% CI, 1.03 to 1.96).
However, in the recessive genetic model, we found that
the miR-196a2 rs11614913 variant homozygote CC was
not significantly associated with the risk of patients in
comparison with wild-type homozygote TT and
heterozygote CT (p = 0.48, OR, 082; 95% CI, 0.62 to
1.25). Additionally, we analyzed the association between
miR-196a2 rs11614913 genotypes and the NSCLC risk
in the subgroups of age, sex, smoking status, and family
history of cancer. A significant association was observed
between the miR-196a2 rs11614913 (CT/TT) genotype
and the NSCLC risk in the subgroups of those who were
aged over 60 years (p < 0.05, OR, 1.43; 95% CI, 1.01 to
2.03), male (p < 0.01, OR, 1.53; 95% CI, 1.09 to 2.16),
smokers (p < 0.05, OR, 1.49; 95% CI, 1.05 to 2.13), and
those without family history of cancer (p < 0.01, OR,
1.55; 95% CI, 1.09 to 2.21). 
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miRNA profiling studies have revealed that many
miRNAs are up-regulated or down-regulated in different
types of human cancers and that most of them are down-
regulated [5]. The expression of miR-196a2 reportedly
correlates with multiple kinds of malignant tumor.
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Table 2. Continued
Variables
n (%)
Genotypes Patients (n=406) Controls (n=428) OR (95% CI)
p-value
Smoking status
Smokers
Non-smokers
Family history of cancer
No
Yes
T allele
C allele
TT
TC
CC
TC/CC
CC vs TC+TT
T allele
C allele
TT
TC
CC
TC/CC
CC vs TC+TT
T allele
C allele
TT
TC
CC
TC/CC
CC vs TC+TT
T allele
C allele
TT
TC
CC
TC/CC
CC vs TC+TT
351 (50.7)
341 (49.3)
080 (23.1)
191 (55.2)
075 (21.7)
266 (76.9)
075 (21.7)
065 (54.2)
055 (45.8)
016 (26.7)
033 (55.0)
011 (18.3)
044 (73.3)
011 (18.3)
327 (50.6)
319 (49.4)
075 (23.2)
177 (54.8)
071 (22.0)
248 (76.8)
071 (220.)
089 (53.6)
077 (46.4)
021 (25.3)
047 (56.6)
015 (18.1)
061 (74.7)
015 (180.)
307 (54.1)
261 (46.0)
088 (31.0)
131 (46.1)
065 (22.9)
196 (69.0)
065 (22.9)
159 (55.2)
129 (44.8)
046 (31.9)
067 (46.5)
031 (21.5)
098 (68.6)
031 (21.5)
344 (55.0)
282 (45.0)
100 (32.0)
144 (46.0)
069 (22.0)
213 (68.1)
069 (22.0)
122 (53.0)
108 (47.0)
034 (29.6)
054 (47.0)
027 (23.5)
081 (70.4)
022 (23.5)
1.00
1.14 (0.91 - 1.43)
1.00
1.60 (1.10 - 2.33)
1.27 (0.81 - 1.99)
1.49 (1.05 - 2.13)
0.93 (0.64 - 1.36)
1.00
1.04 (0.68 - 1.60)
1.00
1.42 (0.70 - 2.87)
1.02 (0.42 - 2.49)
1.29 (0.66 - 2.52)
0.82 (0.38 - 1.76)
1.00
1.19 (0.95 - 1.48)
1.00
1.64 (1.13 - 2.38)
1.37 (0.88 - 2.14)
1.55 (1.09 - 2.21)
1.00 (0.68 - 1.45)
1.00
0.98 (0.66 - 1.46)
1.00
1.41 (0.72 - 2.75)
0.90 (0.39 - 2.07)
1.24 (0.66 - 2.34)
0.72 (0.35 - 1.46)
<0.24
<0.05
<0.05
<0.72
<0.85
<0.55
<0.46
<0.61
<0.12
<0.03
<0.01
<0.98
<0.91
<0.4
<0.51
<0.36
OR: odds ratio, CI: confidence interval.
p-value was revealed by two-sides Chi-square test.
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Accordingly, the functional variant rs11614913 is a
candidate biomarker that may influence the tumor risk
[16]. Thus, in our present study, we first evaluated the
case-control studies in a Korean population with regard
to whether the miR-196a2 rs11614913 T/C polymor-
phism is associated with risk factors in NSCLC lung
cancer patients. 
miRNAs are an evolutionarily-conserved and
abundant class of small silencing RNAs [3,17]; and they
are expressed in limited developmental stages or in
specific tissues or cells, which suggests that they may be
involved in the cell differentiation and maintenance of
the properties of different cells [5,6]. In addition, they are
involved in orchestrating the growth, development,
function, and stress responses of various organs [18].
Although miRNA studies are generally focused on the
cancer field, miRNAs also appear to play a key role as
regulators of the growth, development, function, and
stress responsiveness in the cardiac field [19-22].
Recently, a few studies have examined the association
between cancer risk and the miR196a2 rs11614913 C/T
polymorphism on human cancers and the CC genotype
of this polymorphism could be related to decreasing
survival in lung cancer [15]. In addition, the has-mir-
196a2 TC and TT were associated significantly with a
decreased risk of breast cancer [23], and the association
with congenital heart disease could be established by
altering the expression of mature miR-196a and the
binding activity of the target mRNA [24]. This SNP was
also shown to be associated with lung cancer
susceptibility; that is, a statistically significant increase in
the expression of the mature miR-196a is not preceded
by changes in the levels of lung cancer tissue [16].
Interestingly, the miR-196a2 rs11614913 CC genotype
poses a more frequent increase in risk for cancer
patients. Therefore, the miR-196a2 rs11614913 CC
genotype seems to be an important factor in lung cancer
development and survival. In another study involving
1009 patients with breast cancer and 1093 healthy
Chinese controls, the hsa-mir-196a2 CC and CC/CT
genotypes are associated with a significantly increased
risk of breast cancer [25]. In addition, mir-196a2
rs11614913 C/T polymorphisms are associated with a
significantly increased risk of dilated cardiomyopathy in
a dominant model [26]. In our present study, the result
was similar to the corresponding genotype frequencies
observed [16] and significant associations were observed
for the miR-196a2 rs11614913 CT/CC genotypes with
increased risk of NSCLC in a dominant model. In
addition, our results reveal that after adjusting for age,
sex, smoking status and without family history of cancer
in a comparison with wild-type carriers there appears to
be an association between a significantly increased risk
of NSCLC and variant genotypes of the miR-196a2
rs11614913 CT/CC genotypes. Therefore, miR-196a2
rs11614913 may influence role regulation processes in
Korean NSCLC patients. However, we are not observed
association between the homozygous miR-196a2
rs11614913 CC polymorphism and the risk of NSCLC
lung cancer patients in the recessive genetic model; nor
did we find any significant associations among different
stratified subgroups. Further study is needed
comprehensive approach for all the genes of a Korean
population with a sufficient number of subjects.
Our study had the power of >82% in each gene to
detect an OR of 1.5 (assuming dominant effect, with
minor allele frequency of 0.1 and ǯ = 0.05).
In conclusion, this case-control study provides
evidence that miR-196a2 rs11614913 C/T polymor-
phisms are associated with a significantly increased risk
of NSCLC in a dominant model, indicating that
common genetic polymorphisms in miR-196a2
rs11614913 are associated with NSCLC. Our knowledge
of the effects of miR196a2 rs11614913 polymorphisms
on the risk of NSCLC requires confirmation by
additional larger studies.
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